|Awarded On||November 19, 2014|
|Title||New antibody therapy for treating leukemia|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Chengcheng Zhang|
Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults. Despite continuous treatment, the majority of the patients relapse within 5 years. Leukemia stem cells (LSCs) may be responsible for the relapse of disease following a remission brought about by conventional chemotherapy, and new molecular targets and therapeutic approaches need to be identified to effectively inhibit LSC activity.
Our research has indicated that several members of the inhibitory receptor LILRB family supports the self-renewal and survival of human leukemia cells. We found that several members of the LILRB family are highly expressed on AML cells and their expression negatively correlates with t...